Patent Application
20240042147
The present application claims priority to European Patent Application No. 22188457.0 filed on Aug. 3, 2022, the contents of which are incorporated herein by reference in their entirety.
The present disclosure relates to a dry powder inhaler, i.e. a device for dispensing a powdered medicament preparation by inhalation. The device is in particular a portable, multiple-dose, breath activated dry powder inhaler without propellant gas, equipped with a metering device which dispenses doses delivered from a medicament container.
Inhalers are hand-held portable devices that deliver medication directly to the lungs. One class of inhalers is passive dry powder inhalers (“DPI”). A passive DPI is a patient driven device wherein the action of breathing in through the device draws the powder formulation of a medicament into the respiratory tract. DPIs are well recognized as devices for drug delivery to the lungs for treatment of pulmonary and systemic diseases. They can generally be divided in: i) single-dose (unit-dose) inhalers, for the administration of an individual dose of the active ingredient/s contained in capsule or blister loaded into the device and punctured by the patient immediately before use; ii) pre-metered multi-dose inhalers containing a series of blisters or capsules with the active ingredient/s formulation or iii) reservoir inhalers containing a larger amount of the powder formulation of active ingredient/s, corresponding to multiple doses, which is metered from a storage unit just before inhalation.
Document WO 2004/012801, by the same Applicant, discloses a reservoir inhaler (type iii) which is a dry powder inhaler comprising a casing with a lower shell and an integral cover pivotably coupled to the lower shell. The lower shell delimits a mouthpiece and the integral cover is movable between a closed position in which the mouthpiece is enclosed and hidden by the integral cover and an open position in which the mouthpiece is exposed for use. The lower shell houses a container for storing a powdered medicament, a metering member having a dosing recess to be filled with a dose of the powdered medicament and an inhalation channel in communication with the mouthpiece. The dosing recess is cup shaped and presents a circular edge. The metering member is moveable between a filling position, in which the dosing recess is in alignment with an opening of the container so as to be filled by gravity with a dose of the powdered medicament, and an inhalation position, in which the dosing recess is in alignment with a vortex chamber connected to an inhalation channel for enabling inhalation of the dose of the powdered medicament contained in the dosing recess. The powder inhaler further comprises a protective member which is slidingly moveable on the metering member between a closed position, in which the protective member covers the dosing recess of the metering member if the metering member is in an inhalation position, and an open position, in which the protective member exposes the dosing recess thereby enabling inhalation of the dose of the powdered medicament contained in the dosing recess. The protective member is coupled to an inhalation actuated mechanism in such a manner that the inhalation actuated mechanism moves the protective member from its closed position to its open position if there is an inhalation suction force exerted by a user which exceeds a predetermined level.
Documents WO 2016/000983 and WO 2021/105440, by the same Applicant, discloses a dry powder inhaler (reservoir inhaler) similar to the one of WO 2004/012801. The paper “Expert Opin. Drug Deliv. (2014) 11(9), 1497-1506 by Corradi M. et al.” also discloses a dry powder inhaler (NEXThaler® DPI) by the Applicant.
The dosing recess of the cited prior art documents has a spherical cup shape with a circular edge (in top view) and is usually configured to house a dose of 5-10 mg of powdered medicament. This means that the DPI is configured to deliver such dose through each inhalation.
There could be however the need of delivering powdered medicaments in doses greater than the doses delivered by the prior art inhalers, for instance greater than 10 mg, for each inhalation.
Applicant realized that for doses higher than 10 mg the system of prior art may suffer of some drawbacks and that increasing the diameter of the edge or the height of a spherical cup shaped dosing recess may imply modification of other components of the known DPIs, which should be designed anew and produced through specifically made moulds.
In a first embodiment, the present disclosure provides a dry powder inhaler of type iii (reservoir inhaler) capable of delivering a dose higher than the dose delivered by the prior art, for instance higher than 10 mg, preferably without changing and/or re-designing most of the components of the known DPIs.
According to another embodiment, the present disclosure provides a dry powder inhaler which is able to deliver larger doses maintaining or enhancing the delivery efficiency of the known DPIs.
In particular, the present disclosure provides a dry powder inhaler which allows to completely fill the larger dosing recess with the powdered medicament dispensed by gravity from the container.
In a further embodiment, the present disclosure provides a dry powder inhaler able to completely empty the dosing recess and to ensure the evacuation and delivery of the entire dose through the mouthpiece.
At least one of the above embodiments is substantially achieved by a dry powder inhaler according to one or more of the appended claims and/or of the following aspects.
In accordance with a 1st independent aspect, a dry powder inhaler comprises:
The dry powder inhaler (DPI) of the disclosure is a reservoir inhaler (type iii) containing a large amount of the powder formulation of active ingredient/s, corresponding to multiple doses, which is metered from a storage unit (container) just before inhalation.
The shape of the dosing recess according to the disclosure allows to receive from the container and to contain a dose of powdered medicament greater than the dose contained in the spherical cup shaped dosing recess of the prior art.
The shape of the dosing recess according to the disclosure allows to fill completely said dosing recess, because no part of the dosing recess lies outside the edge of the opening of the container.
The present disclosure allows to change only the shape of the dosing recess, i.e. the mould for the shuttle and to keep unchanged the other components of the known DPIs.
Therefore, the present disclosure allows to manufacture DPIs able to deliver higher amounts of powdered medicament by employing most of the same elements of the DPIs of the prior art and only a limited number of different elements and by fully exploiting existing production lines.
Other aspects of the present disclosure are disclosed in the following paragraphs.
In a 2nd aspect according to aspect 1, a direction of movement of the shuttle between the filling position and the inhalation position and said major axis delimit between them an angle of 90° and said main axis and the major axis delimit between them a first angle other than 0°.
In a 3rd aspect according to aspect 2, said first angle is between 10° and 30°, optionally said first angle is of 20°.
In a 4th aspect according to any of the previous aspects 1 to 3, the de-agglomerator has two air inlets opening in the vortex chamber, said two air inlets being placed on opposite sides of the vortex chamber and along tangential or substantially tangential inflow directions to form an air vortex in said vortex chamber; in the inhalation position, the dosing recess faces the vortex chamber and is fully enclosed in the vortex chamber; optionally, the dosing recess has opposite ends located along the main axis and, in the inhalation position, each of the opposite ends of the dosing recess is next to one of the air inlets.
In a 5th aspect according to aspect 4, a diametrical line connecting the two air inlets and the main axis delimit between them a second angle other than 0°.
In a 6th aspect according to aspect 4 or 5, the de-agglomerator comprises two curved walls having concavities facing each other, the two curved walls being staggered from each other and delimiting the vortex chamber and the two tangential air inlets; optionally, a diametrical line passing through a free extremity of each of the curved walls and the main axis delimit between them the second angle other than 0°.
In a 7th aspect according to aspect 5 or 6, the diametrical line is parallel to the major axis and the first angle is equal to the second angle.
In an 8th aspect according to the any of preceding aspects 4 to 7, each of opposed ends of the dosing recess is located downstream of the respective air inlet with respect to an air inflow entering through said tangential air inlet.
In a 9th aspect according to any of aspects 5 to 7 or to aspect 8 when according to any of aspects 5 to 7, the vortex chamber is configured to form a clockwise air vortex and the main axis is rotated clockwise with respect to the diametrical line or the vortex chamber is configured to form a counterclockwise air vortex and the main axis is rotated counterclockwise with respect to the diametrical line.
In a 10th aspect according to aspect 6 or to any of aspects 7 to 9 when according to aspect 6, in the inhalation position, the dosing recess is contained within a base circle having a diameter “d” given by a segment extending between the free extremities of the two curved walls.
In a 11th aspect according to any of aspects 1 to 10, the edge of the opening of the container is substantially elliptical or the edge of the opening of the container has two major arched sides and two minor straight sides.
In a 12th aspect according to any of aspects 1 to 11, a perimeter of the dosing recess comprises two parallel straight lines connected by two arcs and the two parallel straight lines are parallel to the main axis or the perimeter of the dosing recess is oval or is an ellipse and the main axis is a major axis of the ellipse.
In a 13th aspect according to any of aspects 1 to 12, the dosing recess has a capacity for a powdered medicament greater than 10 mg, optionally greater than 15 mg, optionally of 20 mg, optionally comprised between 20 mg and 30 mg.
In a 14th aspect according to any of aspects 1 to 13, the dosing recess has a length L measured along the main axis and a width W measured perpendicular to the main axis; optionally, a ratio L/W is greater than 1, optionally between 1.4 and 1.8, e.g. of 1.6.
In a 15th aspect according to any of aspects 1 to 14, a protective member is provided between the shuttle and the vortex chamber; when the shuttle is in the inhalation position, the protective member is slidingly movable on or above the shuttle between a closed position and an open position; in the closed position the protective member fully covers the dosing recess and prevents communication between said dosing recess and the vortex chamber; in the open position the protective member leaves the dosing recess exposed to the vortex chamber.
The shape and position of the dosing recess with respect to the vortex chamber, when the shuttle is in the inhalation position and the protective member is in the open position, ensure a complete emptying of the dosing recess, such that the dose of powdered medicament housed in the dosing recess is entrained in the air flow and directed to the mouthpiece through the inhalation channel.
In a 16th aspect according to aspect 6 or 10, each curved wall is an arc of circumference, optionally a hemi-circumference.
In a 17th aspect according to aspect 10, a width “p” of each air inlet measured along the segment extending between the free extremities of the two curved walls is between d/6 and d/4, optionally the width “p” is d/5.
In a 18th aspect according to aspect 10 or 17, when the shuttle is in the inhalation position, a first minimum distance “s1” between a perimeter of the dosing recess and the curved walls is between d/12 and d/8, optionally the first minimum distance “s1” is d/10.
In a 19th aspect according to one or more of the previous aspects 6, 10, 17 or 18, the de-agglomerator comprises a base wall having a through opening for receiving the powder medicament from the dosing recess when the shuttle is in the inhalation position.
In a 20th aspect according to the previous aspect, the two curved walls extend from the base wall and surround or delimit the through opening.
In a 21st aspect according to one or more of the previous aspects 6, 10 or 17 to 20, the end of the inhalation channel opposite the mouthpiece is placed close or between the two curved walls.
In a 22nd aspect according to one or more of the previous aspects 6, 10 or 17 to 21, each of the two curved walls has a radius “R”, the two curved walls have respective centers and said centers are staggered of a distance “Δ”; optionally, the respective centers are both on the diametrical line.
In a 23rd aspect according to the previous aspect when according to aspect 17, given a thickness “t” of the curved walls: Δ=t+p and d=2R−Δ.
In a 24th aspect according to one or more of the previous aspects, the inhalation channel and the vortex chamber share a common central axis.
In a 25th aspect according to aspect 11 or to aspect 12 when according to aspect 11, the two minor straight sides of the edge of the opening are parallel to the direction of movement of the shuttle.
In a 26th aspect according to the aspect 12, the two arcs of the perimeter of the dosing recess define the opposite ends of the dosing recess.
In a 27th aspect according to aspect 12 or 26 when aspect 12 is according to aspect 10, when the shuttle is in the filling position, a second minimum distance “s2” between the perimeter of the dosing recess and the edge of the opening of the container is between d/12 and d/8, optionally the second minimum distance “s2” is d/10.
In 28th aspect according to aspect 14, the length L is between 8 and 12 mm.
In 29th aspect according to aspect 14 or 28, the width W is between 4 mm and 6 mm.
In a 30th aspect according to the previous aspects 10 and 14, a ratio L/d is between 0.8 and 0.95, optionally of 0.9.
In a 31st aspect according to the previous aspects 10 and 14 or according to aspect 30, a ratio W/d is between 0.4 and 0.8, optionally of 0.6.
In a 32nd aspect according to any of the previous aspects, the container comprises a medicament chamber storing or configured to store the powdered medicament and having said opening.
In a 33rd aspect according to the previous aspect, the medicament chamber is at least in part shaped like a hopper converging towards the opening.
In a 34th aspect according to aspect 32 or 33, the container comprises a desiccant chamber storing or configured to store a desiccant.
In a 35th aspect according to the previous aspect, a permeable membrane separates the desiccant chamber from the medicament chamber.
In a 36th aspect according to aspect 15, the protective member is a plate.
In a 37th aspect according to aspect 15 or 36, a width of the protective member measured along the major axis is greater than a size of the dosing recess measured along said major axis.
In a 38th aspect according to aspect 15 or 36 or 37, an inhalation actuated mechanism is coupled to the protective member and is configured to move the protective member from its closed position to its open position if there is an inhalation suction force exerted by a user through the mouthpiece which exceeds a predetermined level.
In a 39th aspect according to the previous aspect, the inhalation actuated mechanism comprises an inhalation actuated member, optionally shaped like a flap, a coupling member and a resilient element arranged on the coupling member; the inhalation actuated member is coupled to the protective member through the coupling member such that, if there is an inhalation suction force exceeding a predetermined value, the inhalation actuated member is moved from a first position to a second position, thereby causing the protective member to move from the closed position to the open position.
In a 40th aspect according to any of the previous aspects, the dry powder inhaler further comprises the powdered medicament.
In a 41st aspect according to any of the previous aspects, the dry powder inhaler further comprises a cover engageable with the casing to close the mouthpiece.
In a 42nd aspect according to the previous aspect, the shuttle is mechanically coupled to the cover such that an opening of the cover beyond a range of rotational movement from the closed position causes the shuttle to move from the filling position to the inhalation position and closing of the cover causes the shuttle to move back from the inhalation position to the filling position.
In a 43rd aspect according to any of the previous aspects, the dry powder inhaler is the same as or similar to the devices disclosed in WO 2004/012801 or in WO 2016/000983 or in WO 2021/105440 or in paper “Expert Opin. Drug Deliv. (2014) 11(9), 1497-1506 by Corradi M. et al.”, apart from the shape and size of the dosing recess.
In a 43rd bis aspect according to any of the previous aspects, the powdered medicament is a pharmaceutical composition.
In a 44th aspect according to the previous aspect, the pharmaceutical composition comprises one or more phosphodiesterase-4 (PDE-4) inhibitors.
In a 45th aspect according to the previous aspect, the phosphodiesterase-4 (PDE-4) inhibitors are selected from the group consisting of tanimilast, cilomilast, roflumilast, tetomilast, oglemilast, apremilast, piclamilast and a salt thereof.
In a 46th aspect according to aspect 43 or 44, the pharmaceutical composition comprises tanimilast or the administered phosphodiesterase-4 (PDE-4) inhibitor is tanimilast.
In accordance with a 47th aspect, a method of treatment of a respiratory disease comprises the administration of a delivered dose through an inhaler according to any of the previous aspects.
In a 48th aspect according to the previous aspect, the delivered dose is greater than 10 mg.
In a 49th aspect according to aspect 47 or 48, the delivered dose is a pharmaceutical composition.
In a 50th aspect according to the previous aspect, the pharmaceutical composition comprises one or more phosphodiesterase-4 (PDE-4) inhibitors.
In a 51st aspect according to the previous aspect, the phosphodiesterase-4 (PDE-4) inhibitors are selected from tanimilast, cilomilast, roflumilast, tetomilast, oglemilast, apremilast, piclamilast and a salt thereof.
In a 52nd aspect according to aspect 49 or 50, the pharmaceutical composition comprises tanimilast or the administered phosphodiesterase-4 (PDE-4) inhibitor is tanimilast.
A 53rd aspect relates to use of the inhaler of any of the preceding aspects 1 to 46 in the treatment of a respiratory disease.
In a 54th aspect according to aspect 52 or 53, the powdered medicament comprises tanimilast.
In a 55th aspect according to any of the previous aspects, the dosing recess has a volume of greater than 10 mm3, optionally greater than 20 mm3, optionally greater than 25 mm3. The dosing recess may have a volume of 10 mm 3 to 50 mm3, optionally 20 mm 3 to 40 mm3, or optionally 25 mm 3 to 35 mm3.
Further features and advantages will be clearer from the detailed description of preferred but not exclusive embodiments of a dry powder inhaler according to the present disclosure.
With reference to the appended drawings,
The dry powder inhaler 1 comprises a casing 2 and a cover 3 being pivotably or rotatably coupled to the casing 2. As can be taken from
The casing 2 is a closed shell made of thermoplastic materials (e.g. ABS and polycarbonate) and comprises lateral sides, an upper side and a lower side (upper and lower with respect to the orientation of the powder inhaler 1 of
The mouthpiece 4 protrudes from the upper side and has an external shape of truncated cone tapering towards an opening 6 fashioned in a top portion (smaller base) of the mouthpiece 4.
The cover 3 is hinged to the casing 2 and can be rotated between a closed position, shown in
The powder inhaler 1 comprises a container 7 for storing a powdered medicament, an inhalation channel 8 connected to the opening 6 of the mouthpiece 4 and a dispensing device 9 (
As is shown in
The container 7 comprises a medicament chamber 11 storing the powdered medicament and a desiccant chamber 12 storing a desiccant for absorbing moisture that may have entered the medicament chamber 11.
The desiccant chamber 12 is separated from the medicament chamber 11 by a separate permeable membrane 13. This permeable membrane 13 is of a different permeability than the permeability between either the desiccant or the medicament to the outside environment. The permeability of the membrane 13 can be achieved, for example, by making it of a different material and/or a thinner section than the main body of the container 7. Foils may be used to seal both the medicament chamber 11 and the desiccant chamber 12. The container 7, in particular the medicament chamber 11, is filled or is configured to be filled with an amount of powdered medicament corresponding to a plurality of doses, e.g. up to 100-200 doses. For instance, the powdered medicament is a pharmaceutical composition.
The desiccant is contained in a housing able of being inserted in the desiccant chamber 12 or the desiccant is in the form of a single tablet able of being inserted in the desiccant chamber 12. The desiccant is or comprises molecular sieves made of a material with pores of uniform size, for instance alkaline salts of aluminosilicates, called zeolites, or aluminophosphates or porous glass or active carbon or artificial zeolites. The molecular sieves are configured to absorb small molecules such as molecules of water. The desiccant may also be a silica gel.
The dispensing device 9 comprises a metering device 14 having a dosing recess 15. The metering device 14 shown in the attached Figures comprises a shuttle 16 shaped like a plate and provided with said dosing recess 15 which is formed or fashioned in a face of the shuttle 16.
The dispensing device 9 is movable, with respect to the container 7 and with respect to the inhalation channel 8, between an idle state (
The medicament chamber 11 is at least in part shaped like a hopper having walls converging towards the opening 17, as visible in
The shuttle 16 is placed between the sub-assembly 10 and a bottom wall of the casing 2. The shuttle 16 is shaped like a plate made of a single piece of plastic, e.g. acrylonitrile butadiene styrene copolymer (ABS).
The shuttle 16 is slidingly moveable between a filling position (
The shuttle 16 is mechanically coupled to the cover 3 such that an opening of the cover 3 beyond a range of rotational movement from the closed position causes the shuttle 16 to move from the filling position to the inhalation position. Closing of the cover 3 causes the shuttle 16 to move back from the inhalation position to the filling position.
As shown in
The metering device 14 further comprises a protective member 18 provided between the shuttle 16 and the inhalation channel 8. The protective member 18 is a plate arranged between the second opening of the inhalation channel 8 and the shuttle 16. The protective member 18 is parallel with respect to the shuttle 16 and is slidingly movable on or above the shuttle 16 between a closed position and an open position.
In the closed position, the protective member 18 is shifted backwards towards the second opening of the inhalation channel 8 and towards the container 7. In the closed position, a rear part of the protective member 18 may at least in part close the second opening of the inhalation channel 8. In the open position, the protective member 18 is shifted forward towards a wall of the casing 2. In the open position, a rear part of the protective member 18 leaves the second opening of the inhalation channel 8 open. The protective member 18 is in the closed position when the shuttle 16 is in the filling position (
Therefore, the metering device 14 is configured to take the three different states cited above (idle, armed, triggered) and these states are determined by the positions of the shuttle 16 and of the protective member 18.
In the idle state (
The dispensing device 9 further comprises a breath or inhalation actuated mechanism 19 coupled to the protective member 18 (
The flap 20 is coupled to the protective member 18 through the coupling member 21 such that, if there is an inhalation suction force exceeding a predetermined value, the flap 20 is moved from a first position to a second position, thereby causing the protective member 18 to move from the closed position to the open position. The flap 20 is placed inside the casing 2 and close to the air intake openings 5. In the first position (
The flap 20 is hinged to the casing 2 in order to rotate between the first position and the second position around a respective rotation axis which is substantially perpendicular to a main axis A-A of the inhalation channel 8. The coupling member 21 is also hinged to the casing 2 in order to rotate between a respective first position and second position around a respective rotation axis which is substantially perpendicular to the main axis A-A of the inhalation channel 8.
The coupling member 21 comprises an arm, not shown, protruding towards the flap 20 and engaged with the flap 20 such that the clockwise rotation of the flap 20 from the first position to the second position causes a counterclockwise rotation of the coupling member 21 from its respective first position towards its respective second position.
The coupling member 21 comprises a prolongation 23 engaging with an opening formed in the protective member 18 in order to move the protective member 18 from the closed position to the open position when the coupling member 21 moves from its respective first position to its respective second position and vice-versa.
The prolongation 23 of the coupling member 21 is also moveably arranged in a longitudinal opening 24 which is formed in the shuttle 16 along its longitudinal direction, such that said prolongation 23 can freely move in the longitudinal opening 24, while a movement of the shuttle 16 from the inhalation position to the filling position causes the prolongation 23 of the coupling member 21 to abut against an edge of the longitudinal opening 24 thereby moving the coupling member 21 back into its initial first position.
The dry powder inhaler 1 further comprises a de-agglomerator 25 that is coupled to the second end of the inhalation channel 8 opposite the mouthpiece 4. Also the de-agglomerator 25 is part of the sub-assembly 10.
The de-agglomerator 25 delimits a vortex chamber 26 and is constructed such that it generates a cyclonic airflow resulting in a strong velocity gradient. The protective member 18 is slidable on the shuttle 16 between its closed position, in which is covers the dosing recess 15, and its open position, in which it exposes the dosing recess 15 to the de-agglomerator 25 and the inhalation channel 8 when the metering member 14 is in the inhalation position, so that the dose of the powdered medicament can be inhaled through the de-agglomerator 25 and the inhalation channel 8 as well as the mouthpiece 4.
The powder inhaler 1 may also comprise a dose counting unit, not shown in the embodiment of the attached drawings, contained into the casing 2 and coupled both to the inhalation actuated mechanism 19 and to the closure of the cover 3 after an efficacious inhalation has occurred. The casing 2 may also comprise a window or an opening for displaying the number of doses taken or the number of doses left in the container 7, this number being counted by the dose counting unit.
As shown in the top views of
An edge 27 of the opening 17 lies in a plane parallel to the face of the shuttle 16 in which the dosing recess 16 is fashioned (
In other embodiments, not shown, the edge 27 of the opening 17 may be elliptical or substantially elliptical.
The de-agglomerator 25 comprises a casing 28 (see
As shown in
The two curved walls 31 extend from the base wall 30 and surround or delimit a through opening 32 fashioned in said base wall 30 (
Each of the two curved walls 31 has an extremity connected to a respective lateral wall 29 and an opposite free extremity 33. A diameter d given by a segment extending between the free extremities 33 of the two curved walls 31 may be considered as the diameter of the vortex chamber 26.
Each free extremity 33 and an adjacent lateral wall 29 delimit an air inlet 34 which opens in the vortex chamber 26. The two air inlets 34 are placed on opposite sides of the vortex chamber and along tangential or substantially tangential inflow directions to form an air vortex in said vortex chamber 26. In other words, the airflow entering through each of the two air inlets 33 is directed tangentially with respect to a circle centered in the vortex chamber 26.
A width p of each air inlet 34 measured along the segment extending between the free extremities 33 of the two curved walls 31 is between d/6 and d/4, e. g. the width p is d/5.
The relations between the radius R, the distance Δ, the width p, the diameter d and the thickness t are the following:
Δ=t+p
d=2R−Δ
Hollows 35 delimited between the lateral walls 29 and radially external surfaces of the two curved walls 31 can be put in fluid communication with the air intake openings 5 through the breath or inhalation actuated mechanism 19.
As shown in
When the user exerts the inhalation suction force exceeding the predetermined value, the protective member 18 moves from the closed position to the open position. In the open position the protective member 18 leaves the dosing recess 15 exposed to the vortex chamber 26. The air flows through the air intake openings 5, into the hollows 35, through the air inlets 34, into the vortex chamber 26 and then into the inhalation channel 8 and out of the mouthpiece 4. The dose of powdered medicament housed in the dosing recess 15 is entrained in the swirling air flow and directed to the mouthpiece 4 through the inhalation channel 8.
As it is evident from the above, the internal mechanisms and functioning of the powder inhaler 1 disclosed above may be substantially the same as those disclosed in documents WO 2004/012801, WO 2016/000983 or WO 2021/105440 by the same Applicant.
The main difference with respect to these documents is the shape, size and positioning of the dosing recess 15, as will be detailed below.
According to the present disclosure, as shown in the top views of
The shape of the perimeter of the dosing recess 15 may be oval or elliptical and the main axis X-X is a major axis of the ellipse. Otherwise, as shown in the attached
Furthermore, the main axis X-X and the major axis Y-Y delimit between them a first angle β other than 0°. Said first angle β may be of about 20°.
The size of the perimeter of the dosing recess 15 is such that, when the shuttle 16 is in the filling position, the edge 27 of the opening 17 of the container 7 encloses the dosing recess 15 or, in other words, the perimeter of the dosing recess 15 is surrounded by or enclosed within the edge 27 of the opening 17, as shown in
This shape of the dosing recess 15 allows to receive from the opening 17 of the container 7 and to house a dose of powdered medicament greater than the dose contained in the spherical cup shaped dosing recess of the prior art. For instance, the length L is between 8 and 12 mm, the width W is between 4 mm and 6 mm and the capacity of the dosing recess 15 according to the present disclosure is greater than 15 mg and is, for instance, of 20 mg. For instance, the dosing recess 15 may have a volume of greater than 20 mm3, for instance about 30 mm3 or about 32 mm3.
In the inhalation position and when the protective member 18 is in the open position, the dosing recess 15 faces the vortex chamber 26 and is fully in the vortex chamber 26. In particular, the dosing recess 15 is contained within the base circle having the diameter d (
Each of the opposite ends of the dosing recess 15 is next/close to one of the air inlets 34 and is located downstream of the respective air inlet 34 with respect to an air inflow entering through said tangential air inlet 34. In the illustrated embodiment, the vortex chamber 26 is configured to form a clockwise air vortex and the main axis X-X is rotated clockwise of the second angle γ with respect to the diametrical line Z-Z. In other embodiments, not shown, the vortex chamber 26 may be configured to form a counterclockwise air vortex and the main axis X-X would be rotated counterclockwise with respect to the diametrical line Z-Z.
When the shuttle 16 is in the inhalation position, a first minimum distance s1 between the perimeter of the dosing recess 15 and the curved walls 31 is between d/12 and d/8, e.g. the first minimum distance s1 is d/10. In the attached
When the shuttle 16 is in the filling position, a second minimum distance s2 between the perimeter of the dosing recess 15 and the edge 27 of the opening 17 of the container 7 is between d/12 and d/8, e.g. the second minimum distance s2 is d/10.
A ratio L/d is between 0.8 and 0.95, e.g. of 0.9 and a ratio W/d is between 0.4 and 0.8, e.g. of 0.6. In the attached
The shape and position of the dosing recess 15 with respect to the vortex chamber 26, when the shuttle 16 is in the inhalation position and the protective member 18 is in the open position, ensure a complete emptying of the dosing recess 15 thanks to the air swirling in the vortex chamber 26. The elongated shape of the dosing recess 15 and its relative position with respect to the air inlets 34 of the vortex chamber 26 allow to collect all the powdered medicament from the dosing recess 15 and to route said powdered medicament into the inhalation channel 8.
Furthermore, a width of the protective member 18 measured along the major axis Y-Y is greater than a size of the dosing recess 15 measured along said major axis Y-Y and a length of the protective member 18 measured along the direction of movement F is greater than a size of the dosing recess 15 measured along said direction of movement F, such that any leak of powdered medicament from the dosing recess 15 and before the inhalation is prevented.
The dry powder inhaler 1 according to the present disclosure may be used with all pharmaceutical compositions that can be dispensed through DPIs with a delivered dose greater than 10 mg per actuation.
In particular, the dry powder inhaler 1 according to the present disclosure may be used in the treatment of respiratory diseases wherein a delivered dose of a pharmaceutical composition greater than 10 mg per actuation is required.
In a preferred embodiment, the powdered medicament stored in the container 7 of the dry powder inhaler 1 according to the present disclosure is a pharmaceutical composition comprising one or more phosphodiesterase-4 (PDE-4) inhibitors selected from the group consisting of tanimilast, cilomilast, roflumilast, tetomilast, oglemilast, apremilast, piclamilast and a salt thereof or other suitable active ingredients. In a more preferred embodiment, the powdered medicament is a pharmaceutical composition comprising tanimilast.
| Number | Date | Country | Kind |
|---|---|---|---|
| 22188457.0 | Aug 2022 | EP | regional |
